Amneal Pharmaceuticals
AMRX
153 hedge funds and large institutions have $666M invested in Amneal Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 25 closing their positions.
3,791% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $92K
55% more capital invested
Capital invested by funds: $430M → $666M (+$236M)
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
18% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 44
6% more funds holding
Funds holding: 144 → 153 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30.3% less ownership
Funds ownership: 66.08% → 35.78% (-30%)
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$17.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$4.68M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.78M |
| 5 |
BlackRock
New York
|
+$3.63M |
Top Sellers
| 1 |
EP
Eversept Partners
New York
|
-$11.2M |
| 2 |
Goldman Sachs
New York
|
-$3.46M |
| 3 |
Millennium Management
New York
|
-$3.09M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.63M |
| 5 |
JP Morgan Chase
New York
|
-$1.78M |
AMRX Hedge Fund Activity: Q4 2023 in Review
153 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2023, worth a combined $666M — up 55% from $430M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AMRX positions and 25 closed out — a net gain of 9 holders — while 52 added to existing stakes and 44 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $17.7M. The largest seller was Eversept Partners, exiting entirely with an estimated $11.2M sold.
- 153 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2023, up from 144 in Q3 2023.
- Funds reported $666M of Amneal Pharmaceuticals stock for Q4 2023, up 55% quarter-over-quarter.
- 34 funds opened new Amneal Pharmaceuticals positions in Q4 2023 and 25 closed out, a net change of +9 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2023 was Rubric Capital Management (New York), an estimated $17.7M added.
- The largest Amneal Pharmaceuticals seller in Q4 2023 was Eversept Partners, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2023.